Interleukin 1β receptor blocker (Anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-03152-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Lamiaa Mohamed Mahmoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Rats, Wistar, Diabetes Mellitus, Experimental, Interleukin 1 Receptor Antagonist Protein. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Diabetic cardiomyopathy (DCM) is a serious common complication of diabetes. Unfortunately, there is no satisfied treatment for those patients and more studies are in critical need to cure them. Therefore, we aimed to carry out our current research to explore the role of two novel therapeutic approaches: one a biological drug aimed to block inflammatory signaling of the IL 1beta (IL1β) axis, namely, anakinra; the other is provision of anti-inflammatory regenerative stem cells. Wistar male rats were allocated into four groups: control group: type 2 diabetes mellitus (DM) induced by 6-week high-fat diet (HFD) followed by a single-dose streptozotocin (STZ) 35 mg/kg i.p., then rats were allocated into: DM: untreated; DM BM-MSCs: received a single dose of BM-MSCs (1 × 10 6 cell/rat) into rat tail vein; DM-Anak received Anak 0.5 μg/kg/day i.p. for 2 weeks. Both therapeutic approaches improved cardiac performance, fibrosis, and hypertrophy. In addition, blood glucose and insulin resistance decreased, while the antioxidant parameter, nuclear factor erythroid 2–related factor 2 (Nrf2) and interleukin 10 (IL10), and anti-inflammatory agent increased. Furthermore, there is a significant reduction in tumor necrosis factor alpha (TNFα), IL1β, caspase1, macrophage marker CD 11b, inducible nitric oxide synthase (iNOS), and T-cell marker CD 8. Both Anak and BM-MSCs effectively ameliorated inflammatory markers and cardiac performance as compared to non-treated diabetics. Improvement is mostly due to anti-inflammatory, antioxidant, anti-apoptotic properties, and regulation of TNFα/IL1β/caspase1 and Nrf2/IL10 pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, Cairo University, Giza, Egypt.
- Department of Physiology, Faculty of Medicine, Cairo University, Giza, Egypt. aya.abdelmageed@kasralainy.edu.eg.
- Department of Histology, Faculty of Medicine, Cairo University, Giza, Egypt.
- Department of Biochemistry, Faculty of Medicine, Cairo University, Giza, Egypt.
Förderung
- Cairo University
Zitieren
APA
Mahmoud, L. M., Mageed, A. A. A. A., Saadallah, J. M., Youssef, M. F., Rashed, L. A., & Ammar, H. I. (2024). Interleukin 1β receptor blocker (Anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03152-1
Vancouver
Mahmoud LM, Mageed AAAA, Saadallah JM, Youssef MF, Rashed LA, Ammar HI. Interleukin 1β receptor blocker (Anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03152-1
BibTeX
@article{Mahmoud2024,
author = {Mahmoud, Lamiaa Mohamed and Mageed, Aya Aly Ashraf Abdel and Saadallah, Jackline Moawad and Youssef, Mira Farouk and Rashed, Liala Ahmed and Ammar, Hania Ibrahim},
title = {Interleukin 1β receptor blocker (Anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-03152-1}
}
EUVIMED